Shanghai XFH Technology (300890.SZ) has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific targets.
Xiangfenghua (300890.SZ) announced that on September 9, 2026, it received a notice from the Listing Review Center of the Shenzhen Stock Exchange (referred to as "SZSE") regarding the application for the issuance of shares to specific objects. The SZSE's issuance and listing review agency conducted a review of the company's application documents for issuing shares to specific objects and concluded that the company meets the issuance conditions, listing conditions, and information disclosure requirements. The SZSE will subsequently report to the China Securities Regulatory Commission to carry out the relevant registration procedures as required.
Shanghai XFH Technology (300890.SZ) announced that it received a notice from the Listing Review Center of the Shenzhen Stock Exchange (referred to as "SZSE") on September 9, 2026, regarding the audit opinion on the application of Shanghai XFH Technology Co., Ltd. to issue shares to specific targets. The SZSE's issuance and listing review institution has reviewed the company's application documents for issuing shares to specific targets and believes that the company meets the issuance conditions, listing conditions, and information disclosure requirements. Subsequently, the SZSE will report to the China Securities Regulatory Commission for the relevant registration procedures as required.
Related Articles
US Stock Market Move | SK Hynix (SKHY.US) expanded its early gains to 5%, reaching a new all-time high.
Tianjin LVYIN Landscape and Ecology Construction (002887.SZ) one of the actual controllers, Lu Yunhui, intends to reduce her holdings by no more than 1%.
JXR (01951): Plans to further develop a translational medicine platform primarily focused on women's health.
US Stock Market Move | SK Hynix (SKHY.US) expanded its early gains to 5%, reaching a new all-time high.
Tianjin LVYIN Landscape and Ecology Construction (002887.SZ) one of the actual controllers, Lu Yunhui, intends to reduce her holdings by no more than 1%.
JXR (01951): Plans to further develop a translational medicine platform primarily focused on women's health.
RECOMMEND
